Anales de la RANM

126 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PRESCRIPCIÓN INAPROPIADA DE MEDICAMENTOS Cruz-Jentoft AJ An RANM. 2022;139(02): 121 - 127 13. Osanlou R, Walker L, Hughes DA et al. Ad- verse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open 2022;12:e055551. 14. Boyd CM, Darer J, Boult C et al. Clinical prac- tice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716–724. 15. Palmer K, Villani ER, Vetrano DL et al. Associa- tion of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta- analysis. Eur Geriatr Med 2019;10:9–36. 16. Korb-Savoldelli V, Boussadi A, Durieux P et al. Prevalence of computerized physician or- der entry systems-related medication prescrip- tion errors: A systematic review. Int J Med Inf 2018;111:112–122. 17. Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Er- rasquín B et al. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mel- litus. J Am Geriatr Soc 2013;61:734–738. 18. Tommelein E, Mehuys E, Petrovic M et al. Po- tentially inappropriate prescribing in commu- nity-dwelling older people across Europe: a sys- tematic literature review. Eur J Clin Pharmacol 2015;71:1415–1427. 19. Santos AP a. L, Silva DT, Alves-Conceição V et al. Conceptualizing and measuring potentially inappropriate drug therapy. J Clin Pharm Ther 2015;40:167–176. 20. Hanlon JT, Schmader KE. The medication ap- propriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging 2013;30:893–900. 21. Mekonnen AB, Redley B, de Courten B et al. Po- tentially inappropriate prescribing and its asso- ciations with health-related and system-related outcomes in hospitalised older adults: A system- atic review and meta-analysis. Br J Clin Pharma- col 2021;87:4150–4172. 22. Beers MH, Ouslander JG, Rollingher I et al. Explicit criteria for determining inappropri- ate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch In- tern Med 1991;151:1825–1832. 23. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medi- cation Use in Older Adults. J Am Geriatr Soc 2019;67:674–694. 24. Gallagher P, Ryan C, Byrne S et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008;46:72–83. 25. O’Mahony D, O’Sullivan D, Byrne S et al. STOPP/ START criteria for potentially inappropriate pre- scribing in older people: version 2. Age Ageing 2015;44:213–218. 26. Delgado Silveira E, Montero Errasquín B, Mu- ñoz García M et al. Mejorando la prescripción de medicamentos en las personas mayores: una nueva edición de los criterios STOPP-START. Rev Esp Geriatr Gerontol 2015;50:89–96. 27. O’Mahony D. STOPP/START criteria for po- tentially inappropriate medications/potential prescribing omissions in older people: ori- gin and progress. Expert Rev Clin Pharmacol 2020;13:15–22. 28. O’Mahony D, Gudmundsson A, Soiza RL et al. Prevention of adverse drug reactions in hospi- talized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized con- trolled clinical trial. Age Ageing 2020;49:605– 614. 29. Blum MR, Sallevelt BTGM, Spinewine A et al. Optimizing Therapy to Prevent Avoidable Hos- pital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled tri- al. BMJ 2021;374:n1585. 30. Kurczewska-Michalak M, Lewek P, Jankowska- Polańska B et al. Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions. Front Pharmacol 2021;12:734045. 31. Lavan AH, Gallagher P, Parsons C et al. STOPP- Frail (Screening Tool of Older Persons Pre- scriptions in Frail adults with limited life ex- pectancy): consensus validation. Age Ageing 2017;46:600–607. 32. Delgado-Silveira E, Mateos-Nozal J, Muñoz García M et al. Uso potencialmente inapro- piado de fármacos en cuidados paliativos: versión en castellano de los criterios STOPP- Frail (STOPP-Pal). Rev Esp Geriatr Gerontol 2019;54:151–155. 33. Reeve E, Gnjidic D, Long J et al. A systematic review of the emerging definition of “deprescri- bing” with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol 2015;80:1254–1268. 34. Soni A, Thiyagarajan A, Reeve J. Feasibility and effectiveness of deprescribing benzodiazepines and Z-drugs: systematic review and meta-analy- sis. Addict Abingdon Engl 2022, DOI: 10.1111/ add.15997. 35. Lee J, Negm A, Peters R et al. Deprescribing fall-risk increasing drugs (FRIDs) for the pre- vention of falls and fall-related complications: a systematic review and meta-analysis. BMJ Open 2021;11:e035978. 36. Bloomfield HE, Greer N, Linsky AM et al. De- prescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis. J Gen Intern Med 2020;35:3323–3332. 37. Ibrahim K, Cox NJ, Stevenson JM et al. A syste- matic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr 2021;21:258. 38. Cardona M, Stehlik P, Fawzy P et al. Effectiveness and sustainability of deprescribing for hospitali- zed older patients near end of life: a systematic review. Expert Opin Drug Saf 2021;20:81–91. 39. Doherty AJ, Boland P, Reed J et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open 2020;4:bjgpo- pen20X101096. 40. Weir KR, Ailabouni NJ, Schneider CR et al. Con- sumer Attitudes Towards Deprescribing: A Sys- tematic Review and Meta-Analysis. J Gerontol A Biol Sci Med Sci 2022;77:1020–1034. 41. Chock YL, Wee YL, Gan SL et al. How Willing